Vaccine Info

Infanrix Vaccine

Authored by
Last reviewed
July 28, 2023

Infanrix® Pediarix™ Combination Vaccine

Infanrix® (STN: BL 103647) is a vaccine combination indicated for active immunization against diphtheria, tetanus, and pertussis, approved in 1997. Infanrix active ingredients are non-infectious substances from tetanus, diphtheria bacteria, and purified proteins of pertussis bacteria. Pediarix™ [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine], Suspension for Intramuscular Injection Initial U.S. Approval: 2002.

In Europe, Infanrix hexa is a vaccine used to protect babies and toddlers against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis (polio), and diseases such as bacterial meningitis caused by the bacterium Haemophilus influenzae type b (Hib). And in New Zealand, INFANRIX-IPV Combined diphtheria-tetanus-acellular pertussis (DTPa) and enhanced inactivated polio suspension for injection.

Infanrix Vaccine Indication

Infanrix is a vaccine indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children six weeks to 7 years of age (before the seventh birthday).

Infanrix Vaccine Dosage

Infanrix is approved for intramuscular administration in infants and children six weeks to 7 years of age (before the seventh birthday) as a 5-dose series. A primary immunization course of 3 doses is administered at 2, 4, and 6 months of age (at intervals of 4 to 8 weeks). The first dose may be given as early as six weeks of age. Followed by two booster doses, administered at 15 to 20 months and 4 to 6 years of age. Preferred administration site: Anterolateral aspect of the thigh for most infants younger than 12 months. Deltoid muscle of the upper arm for most children 12 months of age to 7 years of age. Each 0.5 mL dose contains 30 IU (25 Lf U) of diphtheria toxoid.

Infanrix Vaccine News

February 21, 2022 - The UK Health Agency published the 2022 routine immunization schedule. This publication included immunization programs as well as additional vaccines for individuals with underlying medical conditions.

February 9, 2022 - GSK reported sales of DTPa-containing vaccines (Infanrix, Pediarix, and Boostrix) decreased 4% AER but grew 1% CER. Infanrix/Pediarix sales decreased 14% AER and 9% CER to £543 million, reflecting lower tender volume in Europe and internationally and a change in recommendation for the dosing schedule in Germany, partly offset by increased demand in the US. Boostrix sales grew 9% AER and 14% CER to £521 million, primarily driven by demand recovery and tender volumes in International, as well as higher demand and share in the US.

October 31, 2019 - GSK Korea announced its newly launched Infanrix IPV-Hib, a quintuplet vaccine that covers diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b (Hib). The company hopes that by adding efficiency to the excellence of the existing Infanrix brand, it can become a vaccine that leads to disease prevention for infants and toddlers, said Professor Lee Jin of the Department of Pediatrics at Hanil Hospital.

Infanrix Vaccine Clinical Trials

Infanrix has been tested in over 140 clinical trials. They can be found at this link.